Soft Tissue Sarcoma:Emerging drugs and competitive landscape

Soft Tissue Sarcoma:Emerging drugs and competitive landscape

“DelveInsight Business Research LLP”
DelveInsight’s ‘Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Soft Tissue Sarcoma (STS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

DelveInsight launched a new report on Soft Tissue Sarcoma Pipeline Insight, 2020.

Soft Tissue Sarcoma Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Soft Tissue Sarcoma market. A detailed picture of the Soft Tissue Sarcoma pipeline landscape is provided, which includes the disease overview and Soft Tissue Sarcoma treatment guidelines.

The assessment part of the report embraces in-depth Soft Tissue Sarcoma commercial assessment and clinical assessment of the Soft Tissue Sarcoma pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Soft Tissue Sarcoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

“Soft Tissue Sarcomas (STSs) may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease’s clinical course.”

The key players in Soft Tissue Sarcoma market are:
1. Blueprint Medicines Corporation
2. Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical
3. Karyopharm Therapeutics
4. Deciphera Pharmaceuticals
5. Philogen
6. GlaxoSmithKline
7. Epizyme
8. Eli Lilly and Company
9. Pfizer
10. Aadi Bioscience
11. Sierra Oncology
12. Nanobiotix
13. Taiho Oncology
14. Arog Pharmaceuticals
15. Merck Sharp & Dohme
And many others

Drugs covered:
1. Avapritinib (BLU-285)
2. Anlotinib (AL3818)
3. Selinexor
4. Aldoxorubicin (INNO-206)
5. Ripretinib (DCC-2618)
6. Fibromun (In combination with Doxorubicin)
7. Hensify (NBTXR3)
8. Crenolanib
9. TAS-116
10. GSK3377794
11. ADP-A2M4
12. Tazemetostat (EPZ-6438)
13. AMG 337
14. GB226/APL-501
15. Camsirubicin
And many others

Request for sample pages: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight

Pipeline Development Activities: SOFT TISSUE SARCOMA
The report provides insights into: 
1. All of the companies that are developing therapies for the treatment of Soft Tissue Sarcoma with aggregate therapies developed by each company for the same.
2. Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Soft Tissue Sarcoma treatment.
3. Soft Tissue Sarcoma key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
4. Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
5. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Soft Tissue Sarcoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.  

Scope of the report:
1. The Soft Tissue Sarcoma report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Soft Tissue Sarcoma across the complete product development cycle, including all clinical and nonclinical stages.
2. It comprises of detailed profiles of Soft Tissue Sarcoma therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
3. Detailed Soft Tissue Sarcoma research and development progress and trial details, results wherever available, are also included in the pipeline study.
4. Coverage of dormant and discontinued pipeline projects along with the reasons if available across Soft Tissue Sarcoma.

Report highlights:
1. A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Soft Tissue Sarcoma.    
2. In the coming years, the Soft Tissue Sarcoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 
3. The companies and academics that are working to assess challenges and seek opportunities that could influence Soft Tissue Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
4. A detailed portfolio of major pharma players who are involved in fueling the Soft Tissue Sarcoma treatment market. Several potential therapies for Soft Tissue Sarcoma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Soft Tissue Sarcoma market size in the coming years.  
5. Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Soft Tissue Sarcoma) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

Table of contents:
1. Report Introduction
2. Soft Tissue Sarcoma 
3. Soft Tissue Sarcoma Current Treatment Patterns
4. Soft Tissue Sarcoma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Soft Tissue Sarcoma Late Stage Products (Phase-III)
7. Soft Tissue Sarcoma Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Soft Tissue Sarcoma Discontinued Products
13. Soft Tissue Sarcoma Product Profiles
14. Soft Tissue Sarcoma Key Companies
15. Soft Tissue Sarcoma Key Products
16. Dormant and Discontinued Products
17. Soft Tissue Sarcoma Unmet Needs
18. Soft Tissue Sarcoma Future Perspectives
19. Soft Tissue Sarcoma Analyst Review  
20. Appendix
21. Report Methodology

Download report: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight

Related reports: 

Soft Tissue Neoplasms – Market Insights, Epidemiology, and Market Forecast-2030

Soft Tissue Sarcoma – Epidemiology Forecast to 2030

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/